Search
Peldesine
go.drugbank.com/drugs/DB02568InvestigationalPeldesine is a potent inhibitor of human CCRF-CEM T-cell proliferation. It has undergone phase I trials for the treatment of Human Immunodeficiency Virus (HIV) infections.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesEstrone sulfate
go.drugbank.com/drugs/DB04574ApprovedEstrone sulfate (as estropipate) is a form of estrogen. It has several uses such as: alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelo...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 SubstratesLicofelone
go.drugbank.com/drugs/DB04725ExperimentalDeveloped by the German pharmaceutical company, Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a dual COX/LOX inhibitor and the first member of this new class of analgesic and anti-inf...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsIproniazid
go.drugbank.com/drugs/DB04818ApprovedWithdrawnWithdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2D6 InhibitorsLysergic acid diethylamide
go.drugbank.com/drugs/DB04829IllicitInvestigationalDebate continues over the nature and causes of chronic flashbacks. Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. Some say HPPD is a mani...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesTienilic acid
go.drugbank.com/drugs/DB04831ApprovedWithdrawnTienilic acid, or ticrynafen, is a diuretic drug with uric acid-lowering action which was marketed for the treatment of hypertension. It was withdrawn in 1982 after case reports in the United States suggested a link between ticrynafen an...
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsMethaqualone
go.drugbank.com/drugs/DB04833ApprovedIllicitWithdrawnMethaqualone is a sedative-hypnotic drug that is similar in effect to barbiturates, a general central nervous system depressant. The sedative-hypnotic activity was first noted by Indian researchers in the 1950s and in 1962 methaqualone i...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMaraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalMaraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. I...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTetrabenazine
go.drugbank.com/drugs/DB04844ApprovedA drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesIxabepilone
go.drugbank.com/drugs/DB04845ApprovedInvestigationalIxabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors